Asset Details
Do you wish to reserve the book?
Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate
Do you wish to request the book?
Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate
2015
Overview
Pyruvate dehydrogenase complex (PDHC) is a key enzyme in metabolism linking glycolysis to tricarboxylic acid cycle and its activity is tightly regulated by phosphorylation catalyzed by four pyruvate dehydrogenase kinase (PDK) isoforms. PDKs are pharmacological targets for several human diseases including cancer, diabetes, obesity, heart failure, and inherited PDHC deficiency. We investigated the inhibitory activity of phenylbutyrate toward PDKs and found that PDK isoforms 1-to-3 are inhibited whereas PDK4 is unaffected. Moreover, docking studies revealed putative binding sites of phenylbutyrate on PDK2 and 3 that are located on different sites compared to dichloroacetate (DCA), a previously known PDK inhibitor. Based on these findings, we showed both in cells and in mice that phenylbutyrate combined to DCA results in greater increase of PDHC activity compared to each drug alone. These results suggest that therapeutic efficacy can be enhanced by combination of drugs increasing PDHC enzyme activity.
Publisher
Springer Netherlands,Blackwell Publishing Ltd
Subject
/ Dichloroacetic Acid - chemistry
/ Dichloroacetic Acid - metabolism
/ Dichloroacetic Acid - pharmacology
/ Enzyme Activation - drug effects
/ Humans
/ Male
/ Medicine
/ Mice
/ Original
/ Phenylbutyrates - metabolism
/ Phenylbutyrates - pharmacology
/ Protein Serine-Threonine Kinases - antagonists & inhibitors
/ Protein Serine-Threonine Kinases - chemistry
/ Protein Serine-Threonine Kinases - metabolism
/ Pyruvate Dehydrogenase Acetyl-Transferring Kinase
/ Pyruvate Dehydrogenase Complex - antagonists & inhibitors
/ Pyruvate Dehydrogenase Complex - chemistry
/ Pyruvate Dehydrogenase Complex - metabolism
/ Pyruvate Dehydrogenase Complex Deficiency Disease - metabolism
